Gilead Acquires CymaBay: Liver Cure Leap?
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
- Latest
- Trending
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
Cidara Therapeutics receives $11.1 million milestone payment from Mundipharma for European approval of new antifungal drug, Rezzayo. Analysts see potential ...
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
Sharp HealthCare is leading the way in bringing Apple's Vision Pro VR headset into healthcare. The high-resolution screens and advanced ...
The Federal Reserve is facing pressure to cut interest rates, but evidence suggests that its patience in delaying rate cuts ...
The global Assisted Reproductive Technology market is projected to grow by $8.23 billion by 2027, driven by rising infertility rates ...
The use of robotic-assisted surgery and surgical navigation techniques does not increase the risk of joint infection in total hip ...
Microsoft has resolved the strange bug in Windows 11 that caused chaos with multi-monitor setups, shuffling desktop icons around. The ...
Discover how sleep technology has evolved to include smart mattresses, wearable sleep trackers, and light therapy devices for better sleep. ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.